Alnylam Pharmaceuticals
ALNY
#635
Rank
HK$247.70 B
Marketcap
HK$1,920
Share price
-0.80%
Change (1 day)
50.51%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -HK$32.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -HK$31.98. In 2022 the company made an earnings per share (EPS) of -HK$72.29 a decrease over its 2021 EPS that were of -HK$56.03.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-HK$32.20-55.46%
2022-HK$72.2929.03%
2021-HK$56.03-3.36%
2020-HK$57.97-8.48%
2019-HK$63.347.67%
2018-HK$58.8339.74%
2017-HK$42.1012.94%
2016-HK$37.2738.84%
2015-HK$26.85-32.88%
2014-HK$40.00259.44%
2013-HK$11.13-31.25%
2012-HK$16.1952.94%
2011-HK$10.5830.77%
2010-HK$8.09-8.77%
2009-HK$8.8778.13%
2008-HK$4.98-70.78%
2007-HK$17.0499.09%
2006-HK$8.56-43.88%
2005-HK$15.25-82.33%
2004-HK$86.32-59.23%
2003-HK$211.73

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-HK$13.23-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$290.72-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$60.93 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$2.10-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$13.15-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$29.10-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$24.75-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-HK$15.56-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel